Zonisamide product-specific bioequivalence guidance

This document provides product-specific guidance on the demonstration of the bioequivalence of zonisamide. Please note that no comments have been received for this guideline during the public consultation period.

Keywords: Bioequivalence, generics, zonisamide

Abbreviations: 

• BCS Classification: Biopharmaceutics Classification System
• AUC_0-t: area under the plasma concentration curve from administration to last observed concentration at time t
• AUC_0-72: area under the plasma concentration curve from administration to last observed concentration at 72 hours
• C_max: maximum plasma concentration

Current version - effective 1 January 2026

Zonisamide hard capsules 25, 50 and 100 mg, orodispersible tablets 25, 50, 100 and 300 mg product-specific bioequivalence guidance - Revision 1

AdoptedReference Number: EMA/188397/2025/Rev. 1Legal effective date: 01/01/2026

Document history

Zonisamide hard capsules 25, 50 and 100 mg, orodispersible tablets 25, 50, 100 and 300 mg product-specific bioequivalence guidance

AdoptedReference Number: EMA/CHMP/159882/2016Legal effective date: 01/11/2016Summary:

This document provides product-specific guidance on demonstration of bioequivalence of zonisamide

Draft zonisamide hard capsules 25, 50 and 100 mg, orodispersible tablets 25, 50, 100 and 300 mg product-specific bioequivalence guidance

Draft: consultation closedConsultation dates: 15/07/2015 to 01/11/2015Reference Number: EMA/CHMP/PKWP/253507/2015Summary:

The European Medicines Agency has decided to routinely publish product-specific bioequivalence guidance for a more consistent approach to the assessment of marketing authorisation applications for generic medicines across all authorisation routes available in the European Union. This guidance document describes the specific requirements for the demonstration of bioequivalence for zonisamide.